Get started
Author

Z.B. Dombi

Observed names: Dombi, Zsofia, Z. B. Dombi, Z. Dombi, Zsofia Borbala Dombi, Zsófia B. Dombi, Zsófia Borbála Dombi
ORCID: 0000-0002-0390-4852
Observed ORCID: 0000-0002-0390-4852
OpenAlex ID: A5032529473
The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study
2021 · Elmars Rancans, Zsófia Borbála Dombi, et al. · International Clinical Psychopharmacology · 34
Brain Derived Neurotrophic Factor and Cognitive Dysfunction in the Schizophrenia-Bipolar Spectrum: A Systematic Review and Meta-Analysis
2022 · Zsófia B. Dombi, István Szendi, et al. · Frontiers in Psychiatry · 23
PDF
Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia
2022 · Elmars Rancans, Zsófia Borbála Dombi, et al. · Frontiers in Psychiatry · 16
PDF
Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies
2022 · Réka Csehi, Zsófia Borbála Dombi, et al. · Frontiers in Psychiatry · 14
PDF
The Transdiagnostic Global Impression - Psychopathology scale (TGI-P): Initial development of a novel transdiagnostic tool for assessing, tracking, and visualising psychiatric symptom severity in everyday practice
2024 · Christoph U. Correll, Zsófia B. Dombi, et al. · European Neuropsychopharmacology · 12
Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: evidence from clinical trials, a real-world study, and clinical cases
2021 · György Németh, Zsófia B. Dombi, et al. · Expert Opinion on Pharmacotherapy · 10
PDF
D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside
2024 · Ágota Barabássy, Zsófia Borbála Dombi, et al. · International Journal of Molecular Sciences · 8
Coadministration of Cariprazine with a Moderate CYP3A4 Inhibitor in Patients with Schizophrenia: Implications for Dose Adjustment and Safety Monitoring
2024 · Máté Szabó, Zoltán Hujber, et al. · Clinical Pharmacokinetics · 7
PDF
Clinical Staging in Schizophrenia Spectrum Disorders
2021 · Zsófia Borbála Dombi, Ágota Barabássy, et al. · IntechOpen eBooks · 6
The management of patients with predominant negative symptoms in Slovakia: A 1-year longitudinal, prospective, multicentric cohort study
2024 · Jozef Dragasek, Zsofia Borbala Dombi, et al. · European Psychiatry · 5
Cariprazine and clozapine: a systematic review of a promising antipsychotic combination for treatment-resistant schizophrenia
2025 · Sofia Pappa, Réka Csehi, et al. · The International Journal of Neuropsychopharmacology · 4
Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains
2025 · Agota Barabassy, Réka Csehi, et al. · Pharmaceuticals · 4
PDF
Single trajectory treatment response for predominant negative symptoms: Post-hoc analysis of a clinical trial with cariprazine and risperidone
2023 · Stefan Leucht, Zsófia Borbála Dombi, et al. · Schizophrenia Research · 4
Advancing measurement-based care through triangle of care: Development and feasibility of the Transdiagnostic Global Impression – Psychopathology scale for patients and informants
2025 · Roger S. McIntyre, Zsofia Borbala Dombi, et al. · European Psychiatry · 3
PDF
Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine
2024 · Viktória Meszár, Gabriella Magyar, et al. · Pharmacopsychiatry · 3
The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
2021 · I. Laszlovszky, Z.B. Dombi, et al. · European Psychiatry · 3
PDF
The burden of caring for someone with schizophrenia: A cross country report from Bulgaria, the Czech Republic, Hungary and Russia.
2021 · Sebe Barbara, Ágota Barabássy, et al. · PubMed · 2
Relapse prevention with cariprazine: A focus on sex
2025 · C. Correll, Z. B. Dombi, et al. · European Psychiatry · 1
PDF
Navigating Schizophrenia Treatment: Balancing Symptom Relief and Long-Term Needs
2024 · Agota Barabassy, Zsófia B. Dombi, et al. · IntechOpen eBooks · 1
The Role of Partial Agonists and Specifically Cariprazine in Dual Disorders
2024 · Á. Barabássy, Z. B. Dombi, et al. · European Psychiatry · 1
PDF
Comparing the latent state–trait structure of the PANSS in cariprazine-medicated and placebo-controlled patients with acute schizophrenia
2024 · Jana S. Krückl, Károly Acsai, et al. · European Archives of Psychiatry and Clinical Neuroscience · 1
PDF
Safety during polypharmacy: A post-hoc analysis examining the safety profile of cariprazine with other antipsychotics in the cross-titration phase
2021 · G. Vass, Á. Barabássy, et al. · European Psychiatry · 1
PDF
P.572 Safety with or without treatment: a post-hoc analysis comparing stable patients discontinuing cariprazine treatment versus patients taking cariprazine long-term
2020 · G. Vass, Á. Barabássy, et al. · European Neuropsychopharmacology · 1
Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin‐Concentrating Hormone Receptor‐1 Antagonist RGH‐706 in Healthy and Overweight or Obese Men
2026 · Thomas Brevig, Borbála Szepes, et al. · Diabetes Obesity and Metabolism
PDF
Author response for "Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin-Concentrating Hormone Receptor-1 AntagonistRGH-706in Healthy and Overweight or Obese Men"
2026 · Thomas Brevig, Borbála Szepes, et al. · Publons reviews and discussion
Works count: 56
Citation count: 164
H-index: 7
I10-index: 6
Year
Topic
Type